World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
121
Citations
82957
World Ranking
3534
National Ranking
1945

David H. Johnson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David H. Johnson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 562 publications — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David H. Johnson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David H. Johnson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 121 D-Index — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David H. Johnson is affiliated with The University of Texas Southwestern Medical Center in the United States. Their research focuses primarily on the field of Medicine, with extensive work in subfields including Pulmonary and Respiratory Medicine, Oncology, Sociology and Political Science, Economics and Econometrics, and Public Health, Environmental and Occupational Health.

The scientist's research topics cover a range of issues related to lung cancer and its broader social and economic impacts. Main topics include:

  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Global Cancer Incidence and Screening
  • South African History and Culture
  • Cancer Immunotherapy and Biomarkers
  • Economic and Financial Impacts of Cancer
  • Palliative Care and End-of-Life Issues

David H. Johnson has authored multiple papers in the Journal of Clinical Oncology and other high-profile journals. Notable recent publications include:

  • Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update, 2020, Journal of Clinical Oncology
  • Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update, 2021, Journal of Clinical Oncology
  • Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2022, Journal of Clinical Oncology
  • Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2022, Journal of Clinical Oncology
  • Trajectories of Health Care Contact Days for Patients With Stage IV Non-Small Cell Lung Cancer, 2024, JAMA Network Open

Frequent co-authors in their work include Sheena Bhalla, Vijaya Subbu Natchimuthu, Bryan J. Schneider, Sarah Temin, and Sherman Baker.

Their publications are often found in the following venues:

  • Journal of Clinical Oncology
  • arXiv (Cornell University)
  • Heart Rhythm
  • Journal of the National Comprehensive Cancer Network
  • JCO Oncology Practice

David H. Johnson has also contributed to book publications, including a work published by Edinburgh University Press titled Dreaming of Freedom in South Africa (2020).

Best Publications

  • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

    Alan Sandler;Robert Gray;Michael C. Perry;Julie Brahmer

  • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

    Joan H. Schiller;David Harrington;Chandra P. Belani;Corey Langer

  • Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

    David H. Johnson;Louis Fehrenbacher;William F. Novotny;Roy S. Herbst

  • Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

    Timothy Winton;Robert Livingston;David H Johnson;James Rigas

  • Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

    Roy S. Herbst;Giuseppe Giaccone;Joan H. Schiller;Ronald B. Natale

  • Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

    Giuseppe Giaccone;Roy S. Herbst;Christian Manegold;Giorgio Scagliotti

  • Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

    David A. Eberhard;Bruce E. Johnson;Lukas C. Amler;Audrey D. Goddard

  • Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

    Andrew T. Turrisi;Kyungmann Kim;Ronald Blum;William T. Sause

  • American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003

    David G. Pfister;David H. Johnson;Christopher G. Azzoli;William Sause

  • TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

    Roy S. Herbst;Diane Prager;Robert Hermann;Lou Fehrenbacher

  • Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

    Jeffrey Crawford;Howard Ozer;Ronald Stoller;David H Johnson

  • A meta-analysis of thoracic radiotherapy for small-cell lung cancer.

    Jean Pierre Pignon;Rodrigo Arriagada;Daniel C. Ihde;David H. Johnson

  • Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

    Kathy S Albain;R Suzanne Swann;Valerie W Rusch;Andrew T Turrisi

  • [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].

    Christopher G. Azzoli;Sherman Baker;Sarah Temin;William Pao

  • Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary Results of a Phase III Trial in Regionally Advanced, Unresectable Non-Small-Cell Lung Cancer

    William T. Sause;Charles Scott;Samuel Taylor;David H Johnson

  • Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group

    William Sause;Patricia Kolesar;Samuel Taylor;David H Johnson

  • Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

    Daphne W. Bell;Thomas J. Lynch;Sara M. Haserlat;Patricia L. Harris

  • Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

    Roy S. Herbst;David H. Johnson;Eric Mininberg;David P. Carbone

  • Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

    Gregory A. Masters;Sarah Temin;Christopher G. Azzoli;Giuseppe Giaccone

  • Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

    Nasser Hanna;David H Johnson;Sarah Temin;Gregory Masters

Frequent Co-Authors

John D. Hainsworth
John D. Hainsworth Sarah Cannon Research Institute
Joan H. Schiller
Joan H. Schiller University of Virginia
F. Anthony Greco
F. Anthony Greco Sarah Cannon Research Institute
Yu Shyr
Yu Shyr Vanderbilt University Medical Center
David P. Carbone
David P. Carbone The Ohio State University
Robert B. Livingston
Robert B. Livingston University of Arizona
Frances A. Shepherd
Frances A. Shepherd Princess Margaret Cancer Centre
Leora Horn
Leora Horn Vanderbilt University Medical Center
Henry N. Wagner
Henry N. Wagner Penn State Cancer Institute
Julie R. Brahmer
Julie R. Brahmer Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA opens up diverse options beyond the traditional MD degree. Many students and professionals choose online degree programs to advance their qualifications while maintaining work-life balance. For those interested in healthcare management, consider exploring online mha programs cahme accredited for recognized, flexible graduate education in administration.

Registered nurses looking to further their careers without extensive clinical requirements can look into rn to bsn programs focused on theory, leadership, and research. If you're ready to pursue the highest level of nursing practice, there are options for the shortest dnp program online aimed at qualified candidates seeking a streamlined path.

Want to identify accessible routes to a doctoral degree in nursing? Community discussions and reviews can help you find some of the easiest dnp program reddit recommends, based on student experiences and admission flexibility. These online pathways offer valuable, accredited options to advance your healthcare career with greater convenience.

Best Scientists Citing David H. Johnson

Trending Scientists

Recently Published Articles